BBPWM
CRSP icon

Blue Bell Private Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Blue Bell Private Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.51K Hold
101
– – ﹤0.01% 617
2026
Q1 		$4.8K Sell
101
-62
-38% -$3.27K ﹤0.01% 617
2025
Q4 		$8.55K Buy
163
+41
+34% +$2.46K ﹤0.01% 573
2025
Q3 		$7.91K Sell
122
-85
-41% -$4.88K ﹤0.01% 562
2025
Q2 		$10.1K Hold
207
– – ﹤0.01% 529
2025
Q1 		$7.04K Hold
207
– – ﹤0.01% 542
2024
Q4 		$8.15K Hold
207
– – ﹤0.01% 517
2024
Q3 		$9.72K Hold
207
– – ﹤0.01% 528
2024
Q2 		$11.2K Buy
207
+75
+57% +$4.34K ﹤0.01% 510
2024
Q1 		$9K Sell
132
-80
-38% -$5.73K ﹤0.01% 531
2023
Q4 		$13.3K Hold
212
– – ﹤0.01% 463
2023
Q3 		$9.62K Hold
212
– – ﹤0.01% 426
2023
Q2 		$11.9K Hold
212
– – ﹤0.01% 397
2023
Q1 		$9.59K Buy
212
+50
+31% +$2.43K ﹤0.01% 382
2022
Q4 		$6.58K Hold
162
– – ﹤0.01% 423
2022
Q3 		$11K Buy
162
+10
+7% +$725 ﹤0.01% 360
2022
Q2 		$9K Sell
152
-30
-16% -$1.76K ﹤0.01% 391
2022
Q1 		$11K Buy
182
+69
+61% +$4.33K ﹤0.01% 396
2021
Q4 		$9K Buy
+113
New +$9.87K ﹤0.01% 418

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blue Bell Private Wealth Management's CRSP Position: Q2 2026 in Review

Blue Bell Private Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 101 shares worth $5.51K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

Blue Bell Private Wealth Management first reported a position in CRSP in Q4 2021 and has held it in 19 quarters since. The position peaked at $13.3K in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Blue Bell Private Wealth Management held 101 shares of CRISPR Therapeutics worth $5.51K as of Q2 2026.
  • Blue Bell Private Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Blue Bell Private Wealth Management's portfolio in Q2 2026, its #617 holding.
  • Blue Bell Private Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Blue Bell Private Wealth Management's CRISPR Therapeutics position peaked at $13.3K in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Blue Bell Private Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.